GPRC5D HEK293 Cell Line

Catalog #
78345
$9,400 *
Size: 2 vials
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

Recombinant HEK293 cells constitutively expressing human GPRC5D (the orphan G protein–coupled receptor, class C group 5 member D, NM_018654.1) under the control of a CMV promoter.

Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.

Synonyms
G-protein coupled receptor family C group 5 member D
Product Info
Storage and Usage
Citations
Host Cell Line
HEK293, Human Embryonic Kidney, epithelial-like cells, adherent
Species
Human
Supplied As
Each vial contains 2 x 106 cells in 1 ml of 10% DMSO
Materials Required But Not Supplied
Name Ordering Information
Thaw Medium 1 BPS Bioscience #60187
Growth Medium 1C BPS Bioscience #79532
Formulation

For best results, it is highly recommended to use these validated and optimized media from BPS Bioscience. Other preparations or formulations of media may result in suboptimal performance. 

Thaw Medium 1 (BPS Bioscience #60187):
MEM medium supplemented with 10% FBS, 1% non-essential amino acids, 1 mM Na pyruvate, 1% Penicillin/Streptomycin.

Growth Medium 1C (BPS Bioscience #79532):
MEM medium supplemented with 10% FBS, 1% non-essential amino acids, 1 mM Na pyruvate, 1% Penicillin/Streptomycin plus 50 µg/ml of Hygromycin B

Genbank #
NM_018654.1
UniProt #
Q9NZD1
Mycoplasma Testing

The cell line has been screened to confirm the absence of Mycoplasma species.

Background

The orphan G protein–coupled receptor, class C group 5 member D (GPRC5D) is a retinoic acid-inducible protein with seven transmembrane segments and a short N-terminal extracellular region. The strong and selective expression of GPRC5D in Multiple Myeloma cells, similar to the expression pattern of B-cell maturation antigen (BCMA), makes it a promising target for the treatment of Multiple Myeloma. It is anticipated that GPRC5D will be an alternative CAR T cell target for Multiple Myeloma immunotherapy.